Cvrx Stock Earnings Reports

CVRx delivered a strong Q1 2026 with total revenue of $14.8M (up 20% YoY) driven by 22% growth in the U.S. Key operational progress includes expansion of sales territories (56 U.S. territories), an increase in active implanting centers (257), and higher gross margin (87% vs. 84% a year ago) driven by higher ASPs and manufacturing efficiencies. Management highlighted meaningful reimbursement progress following the January 1 transition to Category I CPT codes, but noted a temporary March softening in Medicare Advantage 30-day prior authorization approvals due to new payer automation and administrative dynamics; appeals are largely overturning initial denials. Clinical progress: BENEFIT-HF randomized trial was activated (first site) and enrolled its first patient, with the potential—if successful—to expand the addressable market from ~339k to >980k patients and materially increase long-term market opportunity. Financials and guidance: Q1 net loss was $13.1M ($0.50/sh); cash and equivalents were $72.3M; management reiterated 2026 guidance of $63–67M revenue, gross margin 85–87%, and operating expense guidance of $103–107M. Management remains focused on three priorities—build a world-class sales org, drive deep adoption at target centers, and reduce barriers to adoption (access, awareness, evidence)—and expects reimbursement processes to normalize as payers adapt to new regulations.